New solution expands RILA access with additional buffer options, helps streamline product selection and delivers greater control WEST DES MOINES, Iowa, May 04, 2026 (GLOBE NEWSWIRE) — Athene, the leading retirement solutions company and subsidiary of Apollo Global Management (NYSE: APO), today announced the launch of Athene Amplify 3.0, a registered index-linked annuity (RILA) designed to expand access to the category. By offering new protection levels and a simplified single-contract structure, Amplify 3.0 enhances the client experience in a RILA market where flexibility, control and ease of use are seen as essential differentiators. Amplify 3.0 builds on the momentum in the RILA market, where sales reached nearly $80 billion across the industry in 2025. Athene has been the top seller of retail annuities in the U.S. for three consecutive...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 04, 2026 (GLOBE NEWSWIRE) — Panoro Minerals Ltd. (“Panoro” or the “Company”) (TSX.V: PML), is pleased to announce that it has entered into an agreement with Clarus Securities Inc. (“Clarus” or the “Lead-Agent”), who has agreed to act as lead agent and sole bookrunner on behalf of a syndicate of agents including Red Cloud Securities Inc., Agentis Capital Markets (First Nations Financial Markets Limited Partnership) and Raymond James Ltd. (together with Clarus, the “Agents”), in connection with a marketed “best efforts” private placement offering, pursuant to Part 5A of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”) and Coordinated Blanket Order 45-935 Exemption from Certain Conditions...

First quarter net sales totaled $121.1 million, up 23.9% over last year; Rail segment sales growth was exceptionally strong improving 38.4%, while Infrastructure sales were also favorable up 5.9%. First quarter net income of $1.5 million was up $3.6 million over last year; EBITDA1 of $5.2 million was up $3.3 million over last year driven by volume and strong gross profit expansion; Selling and administrative expenses as a percentage of sales were 19.0% for the quarter, favorable 240 bps versus last year. Cash flow used in operations in the quarter was $10.4 million, a $15.7 million improvement over last year; Gross Leverage Ratio1 was 1.2x at quarter end significantly improved compared to 2.5x last year. 2026 financial guidance reaffirmed with sales growth and profitability expansion expected for the year.PITTSBURGH, May 04, 2026...

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, including one late-breaking oral presentation, of new data from the Phase 3 ATTRibute-CM study in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology (ESC-HF), taking place in Barcelona, Spain on May 9-12, 2026. Bayer, BridgeBio’s exclusive European licensing partner of acoramidis, will be presenting a late-breaking oral presentation on data from ATTRibute-CM related to acoramidis’ impact on the outcome of outpatient worsening heart failure. Acoramidis is approved as Attruby®...